Viking Therapeutics Gears Up for Significant Investor Conferences
Viking Therapeutics, Inc. (NASDAQ: VKTX), based in San Diego, is an innovative biopharmaceutical company dedicated to advancing groundbreaking therapies aimed at addressing metabolic and endocrine disorders. The company is excited to announce its participation in two prominent upcoming investor conferences that will showcase their advancements and strategic vision.
Conference Participation Details
The company will be attending the following conferences:
Stifel 2025 Healthcare Conference
Viking's management team will engage in a fireside chat and host investor meetings. This conference is a crucial event for showcasing their progress and commitment to improving patient outcomes.
Conference Dates: November 11-13, 2025
Fireside Chat Schedule: November 11, 2025, from 4:40 PM to 5:10 PM Eastern Time
Location: New York, NY
Jefferies 2025 Global Healthcare Conference
This significant event will feature a corporate presentation by Viking management, along with various investor meetings, presenting an opportunity for deeper engagement.
Conference Dates: November 17-20, 2025
Presentation Schedule: November 19, 2025, from 8:00 AM to 8:25 AM Greenwich Mean Time
Location: London, UK
Webcast Availability
For those who cannot attend in-person, a live webcast of the Jefferies presentation will be accessible through the Viking Therapeutics website in the Investors & Media section. A recording of the presentation will also be available on their site following the conference, ensuring broadened access to vital information.
Understanding Viking Therapeutics' Vision
Viking Therapeutics is paving the way for innovative therapies targeting various metabolic and endocrine disorders. The core mission of the company is to leverage its scientific expertise to develop novel therapeutics that effectively enhance patient care and quality of life. They focus on creating first-in-class treatments, including their lead drug candidates.
One of their standout programs is VK2735, a dual agonist linked to GLP-1 and GIP receptors. This compound holds promise for the treatment of obesity, with ongoing Phase 3 clinical trials known as VANQUISH-1 and VANQUISH-2 currently under evaluation.
Preliminary results from earlier trials have shown VK2735 to have a satisfactory safety profile and early indicators of clinical assistance for patients. There are also plans in place for implementing an oral formulation of VK2735 in a Phase 2 trial focusing on obesity treatment.
Expanding Their Therapeutic Reach
Aside from VK2735, Viking is vigorously pursuing VK2809, a groundbreaking small molecule designed to target thyroid hormone receptor beta. This compound has shown exceptional efficacy in Phase 2 studies aimed at treating lipid and metabolic disorders.
In particular, VK2809 has achieved remarkable results in reducing specific fatty liver diseases and associated blood lipid levels, marking it as a pivotal player in Viking’s portfolio.
Additionally, the company is now exploring an array of dual amylin and calcitonin receptor agonists (DACRAs) for obesity treatment and other metabolic issues, showcasing their keen dedication to combatting these profound health challenges.
In rare disease contexts, VK0214 is being developed as an oral small molecule for potential use against X-linked adrenoleukodystrophy (X-ALD). Early-stage clinical trials have indicated that this compound is safe and well-tolerated, showcasing significant clinical activity in patients suffering from specific forms of this rare condition.
Commitment to Advancing Patient Care
Viking Therapeutics is unwavering in its commitment to reform and innovate patient care strategies surrounding metabolic disorders. Their promising pipeline continues to evolve, addressing significant unmet medical needs in patients. The participation in upcoming conferences illustrates Viking's strategic approach to sharing updates and connecting with investors who are as passionate about Improving Lives Through Innovation.
Frequently Asked Questions
What are the upcoming conferences Viking Therapeutics will attend?
Viking Therapeutics will participate in the Stifel 2025 Healthcare Conference and the Jefferies 2025 Global Healthcare Conference.
What is VK2735, and why is it significant?
VK2735 is a dual agonist linked to GLP-1 and GIP receptors, significant for its potential in treating obesity, with ongoing clinical trials underway.
Where can I access the Jefferies presentation?
A live webcast of the Jefferies presentation will be available on the Viking Therapeutics website under the Investors & Media section.
What other products is Viking Therapeutics developing?
The company is also advancing VK2809 for lipid and metabolic disorders and VK0214 for treating X-ALD.
How does Viking Therapeutics plan to engage with investors?
Viking Therapeutics is utilizing these conferences to present clinical advancements and share insights with investors, enhancing stakeholder connection and awareness.
